| A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | AG | AH | AI | AJ | AK | AL | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | curation_date | cohort | age_min | age_max | age_units | number_subjects | tissue_type | tissue_type_term_id | method | response_component | is_model | response_behavior_type | response_behavior | comparison | baseline_time_event | time_point | time_point_units | exposure_material | exposure_material_id | exposure_process | disease_name | disease_stage | publication_reference_id | publication_date | publication_reference_url | signature_source | comments | curator_comments | ||||||||||
7 | descriptive text on Dashboard | curation date YYYY-MM-DD | cohort - any characteristics of the population(s) studied, plus whether the result was taken from a subgroup of the broader cohort tested | age_min - age of youngest subject including both cases and controls | age_max - age of oldest subject including both case and controls | age units | number of subjects - count of case plus control subjects used in the measurement. | tissue type | tissue (Cell Ontology) | method - primary experimental method used to measure the response | response component | signature was derived from a computational model | response behavior type | response behavior (direction, correlation type etc.) | comparison (affected vs control, correlated variable, time vs baseline event etc.) | baseline time event | time point relative to baseline event at which response was measured | time point units | exposure material (NCBI pathogen name) | exposure material (NCBI taxid) | exposure process - method by which immune exposure occurred | disease name | disease stage - reported disease stage(s) of affected subjects | publication reference (PMID) | print publication date or posted date (YYYY-MM-DD) | publication URL | signature source - figure, table or text section | comments and additional details | curator comments | |||||||||
8 | vocabulary, separator | YYYY-MM-DD | free text | number | number | choose from list | number | Free text. Multiple entries must be separated with a semicolon | Choose from list or lookup Cell Ontology code. Multiple entries must be separated by a semicolon, e.g. CL:0000576 (monocyte); CL:0000235 (macrophage). Just the code is also acceptable, e.g. CL:0000576 | Choose from list. Only one entry expected. You can add new methods. | Gene or protein symbols can be separated with commas or semicolons. Cell types or other names must be separated using semicolons. | Y/N | Choose from list. Only one entry allowed. | Choose from list. Only one entry allowed. Add new behaviors if required. | Free text. Use "vs" rather than a dash to separate comparison terms (A vs B). When a reported response behavior with identical response components has been observed across multiple comparisons, they may be combined in one row; separate individual comparison entries with semicolons (A vs C; B vs C). | Free text | Number or free text | Choose from list | free text | Choose from list or use format ncbi_taxid:2697049 | Choose from list. Enter new process if needed. | free text | free text | pmid:nnnnnnnn or nnnnnnnn | YYYY-MM-DD | The URL only, not any associated display text | Free text. Multiple entries allowed if needed | Free text, limit of 255 characters | Free text, no limit | |||||||||
9 | Additional information for curators | Date curation completed | Any characteristics of the population(s) studied, besides age. Example: Hong Kong, Atlanta Also report if the result was limited to a subgroup of the tested cohort, e.g. - subjects suffering adverse events - particular threshold levels of antibody titer level - based on a receiving a particular treatment | Include both case/affected and control subjects | Include both case/affected and control subjects | hours, days, months, years | Often differs by signature within a publication. If number of subjects for a particular signature is not clear in text, use total for cohort. | As reported. The parent tissue of the response components. For cell-type results, the tissue is often PBMCs, but can also be a specific base cell type. For gene expression, the tissue might be a specific base cell type | Cell Ontology IDs for tissues in column “tissue_type”. If there is no matching cell type in the pulldown list, the curator can try to look up a matching term in the Cell Ontology. If there is no appropriate Cell Ontology term, UBERON codes can also be used. | The primary experimental method used to measure the response, e.g. RNA-seq, CyTOF, CITE-seq. | The entities whose response is being measured. Please copy symbols and names exactly as reported in the publication - except spell out greek letters. For cell types, this includes all markers. Examples for a signature with three cell types: T cells CD3+/CD4+/Ki67+; T cells CD3+/CD8+/Ki67+ CD86+ myeloid dendritic cell (DC); CD86+ monocyte | Were the response components chosen using a classification or other model-building strategy? | The type of change being measured, e.g. gene expression, cell-type frequency. | Common values in the pulldown list: - up, down - positively correlated, negatively correlated, correlated - positively predictive, negatively predictive, predictive | Comparisons are typically between two groups, or may reflect a correlation of the response component with some other measured variable. Only report significant results. Examples: - severe COVID-19 cases vs healthy - moderate COVID-19 cases vs healthy; severe COVID-19 cases vs healthy - interferon-stimulated genes in COVID-19 vs healthy - bacterial DNA levels across COVID-19 and healthy subjects Include time comparison if relevant, e.g. 7d vs 0d, where the times are relative to the baseline reference event time (0d). Times before baseline event can be entered as negative numbers, e.g. days before vaccination (7d vs -1d). **Please be concise.** | The reference event from which the time of the experimental response is measured, e.g. hospital admission, onset of symptoms | Time point when response was measured, e.g. “7”, “various”, “0 to 8” | days, months etc. | Enter the pathogen underlying the immune exposure as reported in the publication or use the NCBI Taxonomy term name | NCBI Taxonomy ID of pathogen causing disease | Method by which exposure to pathogen occurred | Reported disease stage(s) of affected subjects in all comparisons entered in row (not including control subjects). We will not attempt to match these directly with the comparisons. Examples include moderate, severe, ICU etc. Pooled can also be added. | Enter the PMID for the article curated, using format pmid:id,such as pmid:32788292, or just the id number, e.g. 32788292 | Partial dates are OK, e.g. YYYY-MM | URL of the article curated. Please use PubMed if available | Figure, table number etc. where the signature was found, as given in the source listed in the publication_reference_url. Multiple entries allowed, i.e. if a result is drawn both from a primary and a supplemental source | Details clarifying any aspect of the signature not captured in other fields. Will appear in Dashboard | Questions or notes for further examination from curator. Will not appear in Dashboard | ||||||||||
10 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 36 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | phospho-CyTOF | plasmablasts (CD3-, CD20-, CD56-, HLA-DR+, CD14-, CD16-, CD11c-, CD123-, CD19lo, CD27hi, and CD38hi); effector cd8 T cells(CD3+, CD8+, CD38hi, and HLA-DRhi) | N | cell-type frequency | up | pooled moderate, severe, ICU, and convalescent COVID-19 (N=19) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU, convalescent (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1B | HLA-DR+/++ is noted specifically for these two cell types | To explain y-axis, found elsewhere that "CD45 is expressed on all leucocytes". | ||||||||||
11 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 99 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | phospho-CyTOF | plasmablasts (CD3-, CD20-, CD56-, HLA-DR+, CD14-, CD16-, CD11c-, CD123-, CD19lo, CD27hi, and CD38hi); effector cd8 T cells(CD3+, CD8+, CD38hi, and HLA-DRhi) | N | cell-type frequency | up | pooled moderate, severe, ICU, and convalescent COVID-19 (N=54) vs healthy (N=45) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU, convalescent (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1B | HLA-DR+/++ is noted specifically for these two cell types | To explain y-axis, found elsewhere that "CD45 is expressed on all leucocytes". | ||||||||||
12 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 36 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | phospho-CyTOF | plasmacytoid dendric cell (CD3-, CD20-, CD56-, HLA-DR+, CD14-, CD16-, CD11c- and CD123+) | N | cell-type frequency | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=19) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU, convalescent (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1C | ||||||||||||
13 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 99 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | phospho-CyTOF | plasmacytoid dendric cell (CD3-, CD20-, CD56-, HLA-DR+, CD14-, CD16-, CD11c- and CD123+) | N | cell-type frequency | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=54) vs healthy (N=45) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU, convalescent (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1C | ||||||||||||
14 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 36 | plasmacytoid dendric cell | CL:0000784 (plasmacytoid dendric cell) | phospho-CyTOF | S6 | N | cytokine/protein level | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=19) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1D | "reduced expression of phosphorylated RPS6, a canonical target of mTOR activation in pDCs...known to mediate the production of interferon-α in pDCs, ... suggests pDCs may be impaired in their capacity to produce IFN-α in COVID-19 patients" | |||||||||||
15 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 99 | plasmacytoid dendric cell | CL:0000784 (plasmacytoid dendric cell) | phospho-CyTOF | S6 | N | cytokine/protein level | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=54) vs healthy (N=45) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1D | "reduced expression of phosphorylated RPS6, a canonical target of mTOR activation in pDCs...known to mediate the production of interferon-α in pDCs, ... suggests pDCs may be impaired in their capacity to produce IFN-α in COVID-19 patients" | |||||||||||
16 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 36 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | phospho-CyTOF | IkappaBalpha | N | cytokine/protein level | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=19) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1E | NFKB Inhibitor Alpha (NFKBIA gene) | |||||||||||
17 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 99 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | phospho-CyTOF | IkappaBalpha | N | cytokine/protein level | down | pooled moderate, severe, ICU, and convalescent COVID-19 (N=54) vs healthy (N=45) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 1E | NFKB Inhibitor Alpha (NFKBIA gene) | |||||||||||
18 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | plasmacytoid dendric cell | CL:0000784 (plasmacytoid dendric cell) | flow cytometry | IFN-alpha | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2A | ||||||||||||
19 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | plasmacytoid dendric cell | CL:0000784 (plasmacytoid dendric cell) | flow cytometry | TNF-alpha | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2A | ||||||||||||
20 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | plasmacytoid dendric cell | CL:0000784 (plasmacytoid dendric cell) | flow cytometry | IFN-alpha; TNF-alpha | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2A | ||||||||||||
21 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IL-6 | N | cytokine/protein level | down | pooled moderate, severe, and ICU COVID-19 (N=17) vs healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
22 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | TNF-alpha | N | cytokine/protein level | down | pooled moderate, severe, and ICU COVID-19 (N=17) vs healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
23 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IFN-alpha; TNF-alpha | N | cytokine/protein level | down | pooled moderate, severe, and ICU COVID-19 (N=17) vs healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
24 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IL-6 | N | cytokine/protein level | down | bacterial stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs bacterial stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
25 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | TNF-alpha | N | cytokine/protein level | down | bacterial stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs bacterial stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
26 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IFN-alpha; TNF-alpha | N | cytokine/protein level | down | bacterial stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs bacterial stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
27 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IL-6 | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
28 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | TNF-alpha | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
29 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | IFN-alpha ; TNF-alpha | N | cytokine/protein level | down | viral stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs viral stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2B | ||||||||||||
30 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 31 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | flow cytometry | p65(Ser529) | N | cytokine/protein level | down | bacterial stimulated, pooled moderate, severe, and ICU COVID-19 (N=17) vs bacterial stimulated healthy (N=14) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU (pooled) | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 2C | ||||||||||||
31 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | IL-6 | N | cytokine/protein level | up | moderate COVID-19 (N=4) vs healthy (N=18); ICU (N=12) vs moderate COVID-19 (N=4); ICU (N=12) vs severe COVID-19 (N=18) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | ||||||||||||
32 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | TNF-alpha | N | cytokine/protein level | up | moderate COVID-19 (N=4) vs healthy (N=18) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | ||||||||||||
33 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | MCP-3 | N | cytokine/protein level | up | ICU (N=12) vs moderate COVID-19 (N=4) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | ||||||||||||
34 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | OSM | N | cytokine/protein level | up | moderate COVID-19 (N=4) vs healthy (N=18); severe (N=18) vs moderate COVID-19 (N=4); ICU (N=12) vs moderate COVID-19 (N=4); ICU (N=12) vs severe COVID-19 (N=18) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | noted as correlated with clinical severity | |||||||||||
35 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | TNFSF14 | N | cytokine/protein level | up | moderate COVID-19 (N=4) vs healthy (N=18); severe (N=18) vs moderate COVID-19 (N=4); ICU (N=12) vs moderate COVID-19 (N=4); ICU (N=12) vs severe COVID-19 (N=18) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | noted as correlated with clinical severity | |||||||||||
36 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | EN-RAGE | N | cytokine/protein level | up | severe (N=18) vs moderate COVID-19 (N=4); ICU (N=12) vs moderate COVID-19 (N=4) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 3 | noted as correlated with clinical severity | |||||||||||
37 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | CXCL10 | N | cytokine/protein level | up | moderate COVID-19 (N=4) vs healthy (N=18) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Fig S6B | ||||||||||||
38 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 34 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | RNA-seq | TAP1, IFITM1, IFIT2, STAT1, IFIT1, IFIT3, DDX60, IFIH1, DDX58, OASL, PML, RSAD2, SP100, HESX1, HERC5, USP18, EIF2AK2, PLSCR1, OAS1, IRF7, SERPING1, PARP9, MX2, IFI27, APOBEC3A, OAS3, SIGLEC1, ATF3, C1QB, BCL2A1, IFNGR2, MGST1, HLX | N | gene expression | up | interferon-stimulated genes in COVID-19 (N=17) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 4G | expanded cohort of 17 covid, 17 healthy, no ages given. | |||||||||||
39 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 34 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | phospho-CyTOF | HLA-DR | N | cytokine/protein level | down | moderate COVID-19 (N=4) vs healthy (N=17); severe COVID-19 (N=13) vs healthy (N=17); severe (N=13) vs moderate COVID-19 (N=4) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 5B | Drawn from same cohort as Fig 1, but not all samples. | |||||||||||
40 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 55 | myeloid dendritic cell | CL:0000782 (myeloid dendritic cell) | phospho-CyTOF | HLA-DR | N | cytokine/protein level | down | moderate COVID-19 (N=15) vs healthy (N=30); severe COVID-19 (N=10) vs healthy (N=30) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 5B | Drawn from same cohort as Fig 1, but not all samples. | |||||||||||
41 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 34 | classical monocyte | CL:0000860 (classical monocyte) | phospho-CyTOF | HLA-DR | N | cytokine/protein level | down | severe COVID-19 (N=13) vs healthy (N=17) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 5B | Drawn from same cohort as Fig 1, but not all samples. | |||||||||||
42 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Hong Kong, China) | 18 | 80 | years | 55 | classical monocyte | CL:0000860 (classical monocyte) | phospho-CyTOF | HLA-DR | N | cytokine/protein level | down | severe COVID-19 (N=10) vs healthy (N=30) | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 5B | Drawn from same cohort as Fig 1, but not all samples. | |||||||||||
43 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 34 | peripheral blood mononuclear cell | CL:2000001 (peripheral blood mononuclear cell) | RNA-seq | S100A12 | N | gene expression | up | severe COVID-19 vs healthy; ICU COVID-19 vs healthy; severe vs moderate COVID-19; ICU vs moderate COVID-19 | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 5C | ||||||||||||
44 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 23 | 94 | years | 64 | blood plasma | UBERON:0001969 (blood plasma) | Olink multiplex inflammation panel | IL-6, TNF, MCP-3, EN-RAGE, OSM, TNFSF14 | N | cytokine/protein level | positively correlated | bacterial DNA levels across COVID-19 (N=51) and healthy (N=18) subjects | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | healthy, moderate, severe, ICU | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Fig 6C | Spearman’s correlation between cytokines and bacterial DNA measured in plasma | cohort and number of subjects taken from earlier blood plasma entry, but can't be sure | ||||||||||
45 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | B cell | CL:0000236 (B cell) | CITE-seq | HLA-DRB5, MTRNR2L8, CD27, S100A4, CCDC88A, ABCA6, MT-ND3, ACTG1, S100A6, MT-CO1, HSPA8, HLA-DPA1, MT-CYB, VOPP1, TRAC, RHOC, RAB11FIP1, RGS1, RPS14, MT-ATP6, AHNAK, RGS10, RGS2, ARL4C, SMARCB1, RNH1, GPR183, VIM, YPEL5, MT-CO3, COTL1, EEF2, ANXA11, LGALS1, GABARAPL2, HLA-DPB1, DYNLL1, SRGN, MT-ND4, ANXA2, MT-ND2, RPL6, CYB561A3, EIF3L, MBD2, LITAF, RPL4, UBE2M, BRK1, CLIC1, MT-ND1, GAPDH, RPS7, TOMM7, GNAS, TNFRSF13B, MT-ATP8 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
46 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | B cell | CL:0000236 (B cell) | CITE-seq | RPS10, H3F3B, ELF1, COBLL1, SF3B1, STK17A, DUSP22, SRRM2, IFI16, DDX5, SRSF10, AFF3, ADAM28, SELL, EIF5A, MACF1, LYST, RIPOR2, LTB, CD22, HLA-C, ZNF92, ILF3-DT, CNOT1, HSH2D, CCNL1, TRA2A, EIF1B, SP110, P2RX5, ATP2B1, REL, PLCG2, SNX29, DDX6, CSNK1G3, VPS13C, HNRNPH1, ATF7IP, HLA-DQB1, ITGA4, BANK1, SP140L, SNHG9, TYMP, IRF8, BST2, USP15, TMEM156, IL4R, ETS1, PPM1K, DDX21, ITPR1, JUN, HLA-A, COL19A1, MYC, MBNL1, HIF1A, TP53INP1, CXCR4, BCL7A, MEF2C, DDX24, HLA-DRB1, PIK3IP1, PRPF4B, MDM4, SMCHD1, UTRN, TCOF1, TAPT1, IFITM2, MTRNR2L12, SMAP2, FCHSD2, SAMD9, TRA2B, HIST1H2AC, PARP14, APLP2, SP100, ADAR, STAT1, LINC00926, HIST1H1C, HIST1H1E, CLEC2D, ISG20, CYBB, MX2, RNF213, RHOB, S100A9, IRF7, S100A8, TMEM123, BIRC3, SAMD9L, TSC22D3, AC007952.4, BTG1, ZFP36L2, AC245014.3, H1FX, LY6E, TRIM22, EPSTI1, EIF2AK2, IFIT3, IFI6, JCHAIN, MX1, XAF1, ISG15, TXNIP, IFI44L | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
47 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | basophil | CL:0000767 (basophil) | CITE-seq | HBB, KLF2, RPL10, MT-ND3, RPL13A, RPLP1, RPS14, RPL23A, RPS27A | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
48 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | basophil | CL:0000767 (basophil) | CITE-seq | RRBP1, OAS3, CCZ1, SPATS2L, ACADVL, USP18, ADAR, PLSCR1, MCM4, ZFC3H1, EIF5A, OAS1, SMC1A, DDX11, PAXBP1, MX2, HNRNPU, IRF7, LAP3, HSPD1, TYMP, IFIT3, IFITM1, PRPF4B, YWHAE, HIST1H1C, HERC5, SP100, HIST2H2AC, SMCHD1, STAT1, LGALS1, EIF2AK2, HIST1H1D, MIR4435-2HG, HIST1H1B, IFI44, EPSTI1, XAF1, IFITM3, IFI6, HIST1H1E, IFI44L, ISG15, MX1, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
49 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster 1) | CL:0000860 (classical monocyte) | CITE-seq | TMEM176B, TMEM176A, RPS4Y1, HLA-DPB1, DDX3Y, RPL27A, RPL23, MT-ND3, HLA-DQA2, HLA-DPA1, RPL7, RPS3A, TXNIP, RPLP1, RPS26, EEF1B2, AC007952.4, RPL10, RPL5, CYP27A1, RBP7, EEF1A1, CYP1B1, GIMAP7, RPL13A, NAP1L1, ZFAS1, RPS20, MTRNR2L1, TPT1, RPL9, RPL21, RPS11, CCL3, RPL15, EIF3L, RPL38, TOMM7, RPS27, RPS2, BRI3, RPL23A, RPL3, RPLP0, EEF2, EIF3E, IER3, EIF4B, RPL4, AC103591.3, RPS24, KLF4, RPL29, P2RY13, RPS6, JAML, RPS14, ALDH1A1, RPL6, SNHG8, KCTD12, MT-ND4L, CCR2, RPL10A, RPS8, FRAT2, SEC11A, LGALS2, HLA-DRA, RPS27A, UBA52, MT-ND2, IL13RA1, RPL13, RPL7A, RPL27, RPS13, KIAA1551, CD36, HNMT, LSM6 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
50 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster 1) | CL:0000860 (classical monocyte) | CITE-seq | TRA2B, S100A9, AFF4, UPP1, EIF5A, CR1, RSRC2, WARS, NR4A1, OASL, ETS2, TRIM22, ACTB, SLC25A37, LGALS1, SGK1, IFIT3, MX2, HIST1H1C, SAMSN1, SECTM1, SPAG9, GRASP, ADAR, MBOAT7, TPM3, SH3BGRL3, H2AFJ, EMP3, ACSL1, CSRNP1, OAS3, FMNL1, CBX6, BST2, SAMD9L, GRN, UBE2L6, FCGR1A, CFL1, NAPA, CTNNB1, PKM, LILRB2, CD300E, CEBPB, OAS1, S100A10, MXD1, MIR22HG, CXCL2, SLC11A1, PLSCR1, BLVRA, SPI1, EAF1, TLE3, ID1, PPDPF, TPM4, DNTTIP2, H1FX, HLA-C, EIF2AK2, PARP14, ZBTB43, EMP1, IRF7, STAT1, TNNT1, CD14, GBP1, HIST1H1D, CTSD, RNF213, KLF10, PSME2, AC020656.1, CFD, SIGLEC1, S100A8, NKG7, RGCC, NAMPT, PLAUR, HBEGF, MIDN, MX1, SELL, MAP3K8, CD63, XAF1, HIF1A, IFI44, TIMP1, XIST, RNASE2, DUSP2, EGR1, JCHAIN, TYMP, ID2, MAFB, HIST1H1E, EPSTI1, PLAC8, ISG15, CLU, G0S2, MT2A, IFITM2, APOBEC3A, LMNA, IFI6, IFI44L, LY6E, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
51 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster 2) | CL:0000860 (classical monocyte) | CITE-seq | RPS4Y1, TMEM176B, TMEM176A, MT-ND3, RPL27A, RPS26, RPL23, HLA-DQA2, LGALS2, RPL38, TPT1, AC007952.4, RPS20, RHOB, RPL21, EEF1B2, DDX3Y, RPS3A, RPS27, TOMM7, RPL7, RPL13A, IER2, RPL10, RPL3, SMIM25, MTRNR2L1, RPL9, RPL23A, RPL5, KLF4, RPLP1, GIMAP7, RPS11, RPS29, EEF1A1, RPS6, RPS27A, FGL2, RPS2, RPL36A, DUSP1, RPL37, JUNB, RPL34, BRI3, LST1, RPL37A, EIF3L, RPL4, RPL24, RPL10A, LTA4H, RPL31, CYP27A1, SERP1, ALDH1A1, RPL15, RPL26, RPL6, GIMAP1, RPS14 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
52 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster 2) | CL:0000860 (classical monocyte) | CITE-seq | GPRIN3, PSMB3, UPP1, OASL, RHOG, EMP3, IFIT3, RRBP1, SIGLEC1, RSAD2, ETS2, LGALS9, EZR, SUPT16H, CFL1, CEMIP2, S100A10, TLE3, AFF4, IFITM1, FCGR1A, TNNT1, LDHA, ZBTB43, DYNC1H1, BST2, TPM4, SLC25A36, SH3BGRL3, PDE4B, ZEB2, EML4, ACTB, PSMB10, HBEGF, TPM3, MIR22HG, GAPDH, PLSCR1, PNPLA8, DDX21, RNF19A, MXD1, EIF2AK2, IRF7, SELL, CTSD, SMCHD1, NAPA, PPDPF, SP100, BCLAF1, PFN1, PDE4D, SLC11A1, PIK3R1, PKM, HLA-C, SYNE2, STAT1, TIMP1, SAMSN1, PSME2, PLAUR, DNTTIP2, RNF213, H1FX, XIST, RNASE2, S100A8, HIST1H1C, IFITM2, IL32, JCHAIN, LGALS1, MX1, HIF1A, IFI44, ID2, CD63, CLU, MAP3K8, EPSTI1, HIST1H1D, LMNA, XAF1, TYMP, ISG15, MT2A, APOBEC3A, IFI6, HIST1H1E, IFI44L, LY6E, G0S2, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
53 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster enriched in ISGs) | CL:0000860 (classical monocyte) | CITE-seq | PPBP, PF4, NRGN, CAVIN2, TUBB1, GNG11, CCL5, CXCL8, TUBA4A, GP9, PRKAR2B, ODC1, IER3, TSC22D1, PTCRA, TREML1, IL1B, CCL3, ACRBP, HIST1H2AC, TMEM40, CLEC1B, C2orf88, CLDN5, RUFY1, CMTM5, KIF2A, HLA-DRB5, NCOA4, MYL9, RGS18, TSPAN33, CD9, GRAP2, MPIG6B, PDZK1IP1, RGS10, LIMS1, MTURN, JUND, ITGA2B, SPARC, GNAS, MAP3K7CL, TPM1, F13A1, NAP1L1, PARVB, XIST, VCL, TLN1, TPM4, IER2, BEX3, TGFB1, 43892, PGRMC1, KLF4, NCK2, CTTN, ILK, PDLIM1, PPP1R15A, MAX, AC147651.1, MMD, RAB27B, TAGLN2, CA2, FOSB, SNCA, MMRN1, IRF1, MPP1, OST4, NFKBIA, PNRC1, AP001189.1, CD83, SOD2, CD151, LGALSL, JUN, AC090409.1, ATP2B1-AS1, DAB2, AP003068.2, KLF2, MT-ND3, MT-CO3, HLA-DPB1, Z93241.1, RAB32, ENKUR, GPX4, DMTN, ACTN1, CD226, TMEM176B, ARHGAP6, GNAZ, RAP1B, CALM3, EIF1, BTG1, LINC00877, CALD1, TUBA1C, SNN, MYLK, YWHAH, RPL10, SNAP23, MT-CO1, TMEM140, GUCY1B1, GP1BA, H3F3A, SMOX, CTDSPL, FLNA, C12orf57, PDE5A, NFKBIZ, PTGS1, FTH1, CCL4, DYNLL1, FOS, CDKN2D, MGAT4B, GAS2L1, ARHGAP18, HIST1H2BJ, AC007952.4, MGLL, RNF11, AC020916.1, FERMT3, MT-ND1, GFI1B, LUCAT1, ITGB3, RPS14, LINC00937, VIM-AS1, TUBB4B, KDM6B, MT-ND2, ZCCHC17, ESAM, SH3BGRL2, PTGS2, ENDOD1, NR4A2, TST, FAM110A, RPS4X, TMEM158, ASAP2, JUNB, ALDH1A1, DOK2, RGS2, MFAP3L, LAMTOR1, TAGAP, MEIS1, MT-CYB, SMIM5, INAFM2, SLC40A1, RDH11, DDX3X, PPP1R14A, FAXDC2, ATF3, ORAI1, PRDX6, DUSP1, C19orf33, EGR1, DUSP2, AGPAT1, FRMD4B, ANKRD9, BCL2L1, VDAC3, LAT, HLA-DPA1, TNFSF4, ERV3-1, ANO6, ITGB1, ITGB5, PDGFA, RPLP1, SELP, DNM3, ITM2B, ABCC3, CYP27A1, ABTB1, RPS27A, RGS1, YPEL5, RPS8, HGD, RPLP0, BRK1, RPS3A, SNRPN, WBP2, TNNC2, ARHGAP21, MTPN, MLH3, STON2, FHL1, SSX2IP, RPL5, TOMM7, SVIP, RPL13, HLA-DQB1, RPL6, TRIM58, CD4, HIST1H3H, SULF2, RPL23, TPT1, EIF1B, MYL12A, OAZ1, EEF2, TMSB4X, UBB, CAMTA1, SLA2, HLA-C, MCUR1, SUSD3, C12orf75, HNMT, C9orf16, LDLRAP1, AQP10, THAP2, RPL21, LTBP1, TAL1, HLA-DMB, KLF6, EEF1A1, A1BG, RPL26, ZNF185, RAB37, CENPT, TMEM91, LRBA, NT5M, EEF1D, PFDN5, RPS23, EGFL7, RPS12, TSPOAP1-AS1, PABPC1, TNF, RPL7A, RPL18, TGFB1I1, RPL15, ELOVL7, RPL7, RPL35A, RPA1, RPS11, HSPA6, HLA-E, RPS7, MT-ATP6, AL360012.1, PLA2G12A, ZDHHC1, CDIP1, RPL19, AP000547.3, BAD, SYTL4 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | Cluster enriched in interferon stimulated genes (ISGs). PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
54 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | classical monocyte (cluster enriched in ISGs) | CL:0000860 (classical monocyte) | CITE-seq | S100A6, B2M, HSP90AA1, MYL12B, TMSB10, CYBA, RPS29, RRAGA, PRDX3, UTY, ANXA5, PTPRC, EFHD2, HLA-A, TMBIM6, FAM20A, MAP2K1, CAPN2, CFL1, TNFSF13B, HELZ2, NDUFA12, PSMA7, NT5C2, FLT3, ITGB7, POLR2L, MEF2A, PGAM1, FCGR1A, ERO1A, SAMHD1, PDIA6, RPN2, DECR1, COX7B, NCKAP1L, SPI1, MRPS18C, UNC93B1, NDUFB3, H2AFJ, ROMO1, ANXA6, ST14, TXN, SH3GLB1, ACTR2, SRI, EIF5A, RRBP1, PSMB6, PML, LAPTM4A, IFNGR1, LMAN2, SMAP2, UBE2L6, PSMA3, SAMD4A, DRAP1, TTC39C, SLFN5, STAT2, LITAF, SERPING1, LAP3, LAMP2, STK17B, ZCCHC2, EZR, SNX2, ARF6, DDX58, ATOX1, PSMB3, VPS29, HLX, POMP, PSMA4, TMED9, DDOST, NMI, GNS, PTEN, ANP32A, RPS26, SDHD, ANXA4, SHTN1, B4GALT5, HLA-B, RAB5IF, F5, PTBP3, SP110, BLOC1S1, LMNB1, VNN1, CHMP5, ENO1, PAG1, AQP9, CD164, MNDA, STAT1, COX6C, SAP30, DDX60, LGALS3BP, USP18, NOP10, TCN2, PIM1, 43891, LARP7, DDX60L, NKG7, H2AFY, CALR, CNIH4, MGST3, SPATS2L, PARP9, HIST1H1C, GIMAP4, IFIT2, S100A11, PPIB, TNFSF10, IFNGR2, NAIP, SP100, DBI, S100A10, CD163, GBP1, AC020656.1, LCP1, PHF11, SAMSN1, IFIH1, GM2A, CTSB, CUL1, DTX3L, LGALS9, CTSL, ITGB2, SHISA5, FPR1, HMOX1, RPS4Y1, LILRB2, PIK3AP1, MGST1, SSB, CSGALNACT2, LILRB4, BLVRA, H1FX, TYMP, VCAN, LDHA, LILRA5, PARP14, IRF7, GRN, ANXA2, HERC5, AGFG1, CD53, APLP2, ADAR, ALOX5AP, TMEM123, PLIN2, RNF213, ISG20, CREG1, SULT1A1, SAMD9, IFI35, MAFB, CMPK2, IFITM1, SPTLC2, SAMD9L, TNNT1, TRIM22, OASL, IFI16, CD63, OAS1, MS4A4A, JCHAIN, PLSCR1, HMGB2, ACSL1, PPA1, FKBP5, SIGLEC1, HIST1H1D, LGALS1, BST2, RSAD2, IFIT1, OAS3, EIF2AK2, DDIT4, OAS2, IFI44, MX2, XAF1, CTSD, EPSTI1, HIST1H1E, IFIT3, S100A9, APOBEC3A, MT2A, S100A8, SELL, PLBD1, S100A12, IFITM2, RNASE2, RETN, MX1, IFI44L, LY6E, ISG15, PLAC8, IFI6, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | Cluster enriched in interferon stimulated genes (ISGs). PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
55 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | CD4-positive, alpha-beta T cell | CL:0000624 (CD4-positive, alpha-beta T cell) | CITE-seq | RPS4Y1, ANXA1, RGCC, IER5, RPS26, RPL27A, TNFAIP3, MT-ND3, MT-ND2, DUSP1, RPS20, TOMM7, MT-ND1, RPL13A, NFKBIA, S100A4, RPS11, MT-ATP6, CXCR4, LGALS1, MT-CYB, TPT1, SRGN | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
56 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | CD4-positive, alpha-beta T cell | CL:0000624 (CD4-positive, alpha-beta T cell) | CITE-seq | EIF2AK2, PIK3IP1, SAMHD1, CHD2, MDM4, TNRC6B, ARGLU1, SYNE2, NKTR, MX1, SRRM2, NORAD, IKZF1, IL32, HNRNPU, NFKBIZ, LEF1, TRAT1, PRRC2C, STAT3, PRPF4B, DDX24, MTRNR2L8, ATM, SFPQ, DDX21, IL6ST, PDE3B, OXNAD1, SATB1, GPRIN3, CYLD, LY6E, MTRNR2L12, EPB41, PIM1, HNRNPH1, TRA2B, SMCHD1, PRMT2, ITGA4, TXK, TXNIP, RNF213, DDX6, SELL, STK17B, MBNL1, MYC, RIPOR2, ETS1, XAF1, ARID5B, XIST, BCL2, HIST1H1E, SOCS3, IFI44L, JCHAIN | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
57 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | CD8-positive, alpha-beta T cell | CL:0000625 (CD8-positive, alpha-beta T cell) | CITE-seq | RPS4Y1, IER5, KLRB1, RPL27A, NFKBIA, RPS20, MT-ND1, RPS14, RPS18, FOS, RPS27A, RPL3, RPL10, RPL13A, MT-CYB, RPL21, EEF1B2, RPS3A, DUSP1, RPL7, SERTAD1, JUNB, RPL13, RPS2, MT-ND3, RPS9, LTB, JUND, RPS11, TPT1, RPL29, RPS3, RPL4, RPS12, RGCC, RPL9, RPS6, TOMM7, MT-ND2, RPL23A, RPL10A, IER2, HOPX, RPS19, IFNG, MT-ATP6, RPL19, RPL18, RPS23, RPL34, RPLP2, JUN, RPS26, MT-ND4, RPS8, RPL7A, RPS7, MT-CO1, RPLP0, RPL23, TNFAIP3, NACA, RPL11, GZMK, UBA52, RPLP1, BTG2, MYADM, RPL18A, GADD45B, EEF1A1, RPS5, RPL26 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
58 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | CD8-positive, alpha-beta T cell | CL:0000625 (CD8-positive, alpha-beta T cell) | CITE-seq | PRRC2C, NDUFA13, RBM39, MYO1F, N4BP1, DOCK10, CTSW, IL32, KIAA1109, KLRD1, CAPN2, KLF3, ELF1, MYH9, AKNA, CD2, ARAP2, ATF7IP, APOL6, CEMIP2, EML4, PARP14, PTPN4, DDX17, HNRNPA3, OGA, AKAP13, EPB41, DOCK8, BZW1, IQGAP2, FLNA, MTRNR2L8, SLFN12L, IFI35, WIPF1, SH2D2A, PHF11, PARP8, PDE4D, TYMP, SRRM2, PDE3B, SF3B1, KTN1, BST2, OASL, DTX3L, PYHIN1, ATG2A, ITGA4, TMEM123, S100A11, IFITM2, HNRNPH1, HCLS1, KIAA1551, ZBP1, CEBPZ, IRF9, SYNE1, HNRNPU, GNLY, USP15, LCP1, SAMD3, MACF1, XIST, BTN3A2, RNF125, SYTL2, ATM, VPS13C, DDX24, H1FX, XCL2, RIPOR2, SELL, SLFN5, ALOX5AP, ARID5B, SP110, PLAC8, SAMHD1, PRF1, MBNL1, TRBC1, CLEC2D, SYTL3, SAMSN1, MX2, HIST1H1C, DDX6, PRPF4B, UTRN, ADAR, TRIM22, MYBL1, TRGC2, IFI16, PARP9, PLSCR1, HIST1H1D, HLA-DRB1, GZMB, STAT1, SMCHD1, ETS1, SYNE2, OAS1, SAMD9, SAMD9L, LY6E, IL7R, RNF213, PIK3R1, EPSTI1, IFITM1, IRF7, ISG20, SP100, MT2A, TXNIP, EIF2AK2, HIST1H1E, JCHAIN, MX1, XAF1, IFI6, IFI44L, ISG15 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
59 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | conventional dendritic cell 1 | CL:0000990 (conventional dendritic cell) | CITE-seq | HLA-DQA2, HLA-DRB5, RPS11, PPP1R14B, RPL27A, RPS20, BRI3, HLA-DPA1, HLA-DPB1, MAP2K2, RPL13A, RPL23, RPS14, RPL10, MTRNR2L1, RPS18, MBD2, RPL29, RPL23A, RPS12, RPS6, RPL31, RPL38, RPS3A, RPLP1, RPL13, RPL27, RPLP0, RPS2, RPL7, RPL18A, SPAG7, EEF1B2, RPS23, RPL7A, RPS7, RPL24, RPL3, RPL35, RPS25 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
60 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | conventional dendritic cell 1 | CL:0000990 (conventional dendritic cell) | CITE-seq | SUB1, FNBP1, TPM3, HLA-A, IDH3A, IRF8, SRP14, HSH2D, IFIH1, RHOA, H3F3B, WAS, PLEK, B2M, HNRNPC, GMPR, HLA-B, PSME2, PLSCR1, PARP14, HNRNPU, 44080, MEF2A, TPM4, PDIA3, FCHSD2, SAMD9, SHTN1, NAPA, EFHD2, CNDP2, SEPHS2, PHF11, SSB, USP18, IFI27L2, IFI35, CHMP5, HNRNPA2B1, PTPRC, SMCHD1, DRAP1, DDX21, CALR, CD164, PRPF4B, PARP9, TRIM22, HSP90B1, LCP1, HIST1H1C, PIM3, HLA-DQA1, ADAR, CAP1, MCL1, UBE2L6, IFI16, OAS2, HIST1H1D, BST2, HSPA5, NAMPT, TYMP, HSDL2, IFI44, KLF10, PPA1, LAP3, MX2, SAMD9L, HLA-DRB1, TXNIP, COX5A, PLAC8, EIF2AK2, DDIT4, SP110, STAT1, HIST1H1E, XAF1, IFI6, EPSTI1, IRF7, JCHAIN, IFITM2, IFI44L, LY6E, ISG20, MX1, ISG15, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
61 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | conventional dendritic cell 2 | CL:0000990 (conventional dendritic cell) | CITE-seq | RPS4Y1, HLA-DQA2, CLEC10A, RPL27A, EEF1B2, RPL13A, MS4A6A, RPS20, RPL23, HLA-DPB1, RPS26, RPS11, RPL3, RPS3A, RPL7, RPS18, RPLP0, TOMM7, RPS6, RPL9, RPLP1, RPS14, HLA-DRB5, RPL23A, RPS2, RPL10, RPS27A, TPT1, RPL21, DDX3Y, RPS8, EIF3L, HLA-DPA1, EEF1A1, MT-ND3, RPS23, RPL5, FCER1A, RPL10A, RPL38, RPL13, SEC11A, RPS16, RPL7A, NOP53, RPS3, ZFAS1, RPS24, BRI3, RPL37A, RPL15, RPL6, RPL29, SNHG8, BATF3, RPL18A, EIF3E, RPS7, RPL31, EIF3F, RPS12, RPL27, RPL24, RPS27, RPS5, LST1 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
62 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | conventional dendritic cell 2 | CL:0000990 (conventional dendritic cell) | CITE-seq | SH3BP5, NEU1, MAP3K8, SAMHD1, PSMB9, TPM4, ZYX, IER2, SAMD9, RHOG, TIMP1, PFN1, IFI35, CMPK2, PTP4A2, CD63, DUSP1, GRASP, STK17B, EIF5A, GLIPR2, ADAR, CFD, OAS3, RBM39, ARPC1B, TPM3, CTSD, TRA2B, HLA-DQA1, YBX3, NEAT1, MBOAT7, HIST1H1C, LGALS9, ACTB, HSPA5, PKM, CLK1, HSP90B1, LAP3, PPDPF, HLA-A, NAPA, CUL1, OAS1, GBP1, SNHG15, CCND3, PDIA3, PIM3, ISG20, PARP9, TOB1, DDIT4, SP110, OAS2, BST2, FOS, EREG, H1FX, HNRNPU, ATF3, CALR, IFIT3, PSME2, RNASE2, HIF1A, CCL3L1, SAMD9L, HIST1H1D, UBE2L6, ZFP36, SELL, PARP14, NAMPT, STAT1, XIST, JCHAIN, RNF213, KLF10, MX2, EIF2AK2, IFI44, AREG, HLA-DRB1, PLSCR1, IFITM1, IRF7, AC020656.1, HIST1H1E, JUN, EPSTI1, IFITM2, TYMP, XAF1, MX1, MTRNR2L8, MT2A, ISG15, LY6E, IFI6, IFI44L, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
63 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | eosinophil | CL:0000771 (eosinophil) | CITE-seq | FOSB, IER5, KLF6, RPS18, JUN, SAT1, IER2, TOMM7, RPL13, RPS27A, RPL13A, NOP53, RPL27A, FOS, RPS3, RPL21, RPL9, RPS26, RPL10, RPL3, RPS2, RPS3A, RPS6, RPS27, RPS12, MT-CYB, RPL32, MT-ND3, TPT1, RACK1, MT-ND2, MT-ND1, RPS8 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
64 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | eosinophil | CL:0000771 (eosinophil) | CITE-seq | MACF1, SYNE2, RNF213, UTRN, SP100, XAF1, HIST1H1E, IFI44L, JCHAIN | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
65 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | granulocyte | CL:0000094 (granulocyte) | CITE-seq | HLA-DPA1, HLA-DPB1, FCGR3A, CDKN1C, HLA-DRB5, TMEM154, RPL10, TOMM7, RPS27, TPT1, RPL4, RGS2, MT-ND3, RPS20, CALM2, RPL21, RPL38, PFDN5, RPS3A, RPL26, RPL30, EEF1B2, RPS2, RPL5, RPS14, RPL34, FGL2, RPS24, RPL23A, RPS27A, RPL11, RPL9, RPL13A, RPL24, EEF1A1, RPS6, CST3, RPL27, RPL29, RPL13, RPS16, RPS12, RPS29, NACA, UBA52, RPS9, RPL6, RPL12, RPL14, RPL37A, RPL37, RPS18, MALAT1, RPL19, RPL8 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
66 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | granulocyte | CL:0000094 (granulocyte) | CITE-seq | CD63, HIF1A, LY6E, APOBEC3A, HSP90B1, IFITM3, MZB1, IFI27, JCHAIN | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
67 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | hematopoietic stem cell | CL:0000037 (hematopoietic stem cell) | CITE-seq | ZFP36, JUND, FOSB, IER2, RGS1, RPL10, RPS14, IER5, NR4A2, GNAS, FOS, MAP2K2, PPP1R15A, RPS11, MAZ, RPL3, EEF1B2, CD7, SEC11A, RPL13A, SERTAD1, RPS3A, RPL19, DUSP1, CNRIP1 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
68 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | hematopoietic stem cell | CL:0000037 (hematopoietic stem cell) | CITE-seq | KTN1, KIF2A, TYMP, H3F3B, PPDPF, CST7, HLA-B, APP, HLA-A, RPS10, SOD2, HLA-DQB1, HSPD1, MSI2, STOM, RNF213, HNRNPDL, JCHAIN, MTURN, PRDX1, ATP5ME, POLR2J3.1, PROM1, RPL36, CDK6, NCOA7, IFIH1, SPTLC2, ADAR, CD9, SOCS2, NPR3, RPS17, PIM1, TRIM22, NEAT1, YWHAE, OAS2, PRKG1, PRSS57, CD44, CEBPZ, MGST1, MTRNR2L12, GLIPR1, APLP2, MIR181A1HG, DDX60, HSP90B1, MT-ND4L, STAT1, IQGAP2, BCL11A, S100A9, MX2, HIST1H2AC, RPL36A, TCEAL4, TFPI, SNHG25, ANXA5, RSAD2, CD99, SAMD9, NPDC1, IRF7, MMRN1, OAS1, MLLT3, SP100, FHL1, HSPB1, NUCB2, ANKRD28, CLU, PARP9, MSRB3, ATP8B4, LAPTM4B, IFI44, SELL, H1FX, PTMS, TPM4, IFI16, MT2A, PLSCR1, EGFL7, ZFP36L2, SAMD9L, H1F0, MDK, YBX3, IFIT1, S100A8, IFIT3, HLA-DRB1, EPSTI1, EIF2AK2, HIST1H1C, BST2, HBB, LY6E, HIST1H1D, HIST1H1E, AVP, XAF1, IFITM3, ISG15, MX1, IFI6, IFI44L, AREG | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
69 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | non-classical monocyte | CL:0000875 (non-classical monocyte) | CITE-seq | TMEM176B, HLA-DQA2, RPL27A, HLA-DRB5, HLA-DPB1, RPL13A, TMEM176A, EEF1B2, RPS20, RPS18, RPS27, RPS6, GIMAP7, RPL9, RPL23, RPS2, RPL23A, RPL10, HLA-DPA1, RPL3, S100A9, RPL10A, RPL27, TPT1, RPLP0, RPS3A, RPL38, RPL13, SNHG8, RPL15, TOMM7, RPL7, RPL5, RPL21, RPL4, P2RY13, RPS11, CTSH, RPS5, EEF1A1, RPS4X, TUBA1B, RPL18A, MT-ND3, MALAT1, DYNLL1, HLA-DRA, RPL35, RPL37A, LSM6, CPVL, RPLP1, RPL12, MTRNR2L1, GNLY, RPL31, RPL34, RPL29, RPS3, MNDA, RPS9, CD48, RPL6 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
70 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | non-classical monocyte | CL:0000875 (non-classical monocyte) | CITE-seq | EIF4G2, LILRA1, ULK1, CSRNP1, CREBRF, TACC1, CALM3, ATG2A, NKG7, AFF4, FUS, ADM, MIR22HG, CYP4F22, ATF3, ID2, CD300E, GLUL, CSTB, FOXO3, ANPEP, ADAM10, H1FX, BCLAF1, MAP1LC3B, RSRC2, EP300, TPM3, TMC6, CCDC85B, FTH1, CLK1, PIK3AP1, RHOC, CCNL1, KLF6, CXCL16, NFKBIZ, TCIRG1, ZFP36, AC020656.1, GRASP, FAM45A, CDKN2D, IFITM1, SLC43A2, ELL2, TRA2B, ARF5, CTSD, RPS27L, POLR2J3.1, LENG8, MAP3K8, MYO9B, XAF1, SCGB3A1, TNF, SNHG15, BLOC1S1, TMSB10, EPSTI1, MDM2, NFKBIA, RNF144B, PIM3, TNNT1, CTNNB1, IFI30, ANXA4, CDKN1A, LILRB1, PPDPF, CFD, ZBTB7A, HIST1H1D, TIMP1, NAMPT, FMNL1, NEAT1, AC020916.1, LILRB2, G0S2, IFI6, KLF10, IFI44L, JCHAIN, MIDN, ISG15, HES4, LY6E, HIST1H1E, MT2A, CD63, APOBEC3A, C1QB, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
71 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | natural killer cell | CL:0000623 (natural killer cell) | CITE-seq | MT-ND3, RPL27A, PTGDS, CD52, RPS4Y1, GIMAP7, MT-CYB, MT-ND2, RPL13A, RPS20, KLRB1, MT-ATP6, CCL4, RPL7, MT-ND1, LYZ, RPL38, FOSB, MT-ND4, RPL3, RPL10, RPS6, CD160, RPL21, EEF1B2, IER5, RPS3A, RPS14, RPS11, RPS18, PTGDR, MT-CO1, RPL27, RPL23A, CLIC3, MT-ND5, RPL9, RPS27, PLEKHF1, TOMM7, TPT1, RPL37A, TUBA1B, RPL13, COQ7, RPLP2, RPL23, MT-ND4L, JUNB, RPS9 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
72 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | natural killer cell | CL:0000623 (natural killer cell) | CITE-seq | CCND2, TMEM123, ZBTB1, ATF7IP, HNRNPU, DTX3L, CEBPB, GNLY, PMAIP1, GZMH, OGA, SETX, CALR, HMGB2, SFPQ, NFKBIA, SRRM2, MIR4435-2HG, EML4, BAX, PARP14, HSH2D, IFITM2, S100A10, TGFB1, FBXO7, IFI16, STAT3, TAP1, TRA2B, UBE2L6, CD79B, CAPN2, FXYD5, TNFAIP3, ARID5B, PPDPF, PSMB10, ZBP1, SYAP1, DDX6, GNAS, TCIRG1, USP15, RAB5IF, ZFP36, HLA-DPB1, IFI35, LGALS9, PRPF4B, CTSW, SEC14L1, UTRN, HSPA5, S100A11, SLA2, FLNA, SP110, TXNIP, TSPYL2, CREM, TRIM22, PSME2, ETS1, HLA-C, PARP9, PRKX, ITGA4, PRF1, SYNE2, GAPDH, OAS2, SH2D2A, SAMD9, CD38, IRF9, RNF213, SELL, MAP3K8, BST2, ADAR, SMCHD1, TYMP, CD74, SP100, HLA-DPA1, ATG2A, PLSCR1, STAT1, PIK3R1, SAMD9L, PDE4D, MX2, OAS1, LAIR2, SYTL3, KLRC1, IFI44, HLA-DRB1, XIST, GZMB, H1FX, LY6E, IRF7, CEMIP2, LGALS1, EIF2AK2, ISG20, HIST1H1D, EPSTI1, MTRNR2L8, IFITM1, ALOX5AP, HIST1H1C, MT2A, IL32, AREG, MYOM2, HIST1H1E, MX1, XAF1, JCHAIN, ISG15, IFI6, IFITM3, IFI44L | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | text says: "differentially expressed genes (DEGs) in each cluster compared with all other cells" | ||||||||||
73 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | plasmablast | CL:0000980 (plasmablast) | CITE-seq | CCT3, SF3B6, ISOC2, SLC38A5, PSMA1, RAN, CLPP, RPL7A, MRPL43, VDAC3, EMC4, ECHS1, RPL8, TIMM17B, ZBTB8OS, TMED3, CTSS, MRPS23, NUDT22, HADHA, SNRPG, TMED2, HNRNPH3, MRPL3, DESI1, PSMD4, SSBP1, C19orf24, PSMB3, SNRPE, SRPRB, MRPL40, HSPD1, C1orf43, PTP4A2, XRN2, ECH1, FDPS, RPL13, ANAPC11, KRAS, PSMA7, LAMTOR5, EZR, EMC3, TKT, HIST1H1E, ACADM, RNF114, TRAPPC1, CCT4, ATP5PO, PIGT, TNFRSF13B, SLC1A4, CD47, SDHB, GABARAPL2, CCT8, SLC25A5, SRSF3, TRIR, LDHB, HARS, GNAI2, MFF, TMPO, MRPL57, MRPL12, FUCA2, UBE2L3, SH3BGRL3, UQCRC2, RNASEH1, CCT5, IMMT, PUM1, B3GAT3, PSMB6, BAK1, MPC1, DECR1, CCDC167, ALKBH7, ARPC5L, BUD31, TMEM208, TLN1, AUP1, NUCB2, PSMA4, ATF4, ARL6IP5, SNRPC, SNRPB, SF3B2, HNRNPF, DPM2, MCL1, NDUFS8, GTF3C6, PLP2, SARS, GMPPB, CHMP2A, PHF3, NPC2, PSMC4, FKBP1A, IRF1, GNB2, VSIR, SOD1, UBE2I, CLEC2D, CTSD, POLR2K, NUDC, MRPS7, RAP1B, ETFA, OS9, RBMX, CIRBP, GRK6, SRI, SAP18, TMEM30A, DBI, YWHAQ, ERP44, S100A11, MRPL22, YBX3, SRA1, UQCRC1, MRPS11, UAP1, OXA1L, TMEM14B, WDR83OS, MRPL55, PSMD2, VAMP8, SRSF9, FAM173A, POLR1D, BRK1, TMCO1, BLOC1S1, SPTLC1, DNAJC4, NDUFA9, PRDX2, SRSF7, DAZAP2, C19orf53, SLC25A4, SMC1A, ALG14, SEMA4A, MRPS34, MAPRE1, PRMT1, GLRX5, C1D, SDF4, RAC1, LITAF, PTGES3, CYB561D2, NDUFV2, RAD21, CHCHD1, THOC7, SUCLG1, TAP1, HNRNPAB, DDT, CCT7, UBN1 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
74 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | plasmablast | CL:0000980 (plasmablast) | CITE-seq | GON4L, CHMP4B, CEP128, VPS4B, PJA2, ATF5, RAB14, ATOX1, ERAP2, FAM133B, BTN3A2, GOLGA2, ELL2, ZDHHC12, PMPCB, NAA20, GSDMD, NOL8, SPEN, TARSL2, HNRNPDL, SRP54, TSEN15, DUSP5, ACAA1, LLPH, NCKAP1L, ARSA, PAICS, APOL1, RNPS1, DAPP1, LGALS1, COPZ1, ARID5B, GLO1, LIMS1, MAP3K2, ARHGAP15, FKBP8, RBM39, AP1G1, ZNF37A, CFLAR, CTSH, 44076, CLPTM1, DNAJC3, MAGT1, NDUFA11, MEF2A, CDC16, CHMP4A, PRKCSH, GOLGA3, RABGAP1L, AC007952.4, PPA1, TTC3, BMS1, CEBPZ, PCBP1, CAPZA1, TRIP11, HIBCH, RPS26, ADAM10, CALR, RPS10, CLIP1, ACTR2, PNKD, SEC14L1, APOL6, NIN, BCAP31, B4GALT1, TMEM259, VPS13C, PTK2B, MSL3, SSR1, DLG1, RTF1, CPSF6, ITGB7, RPS21, LMO4, KLF13, SGK1, EIF4G1, EIF4G2, MTRNR2L8, TRANK1, GRB2, MUC20-OT1, TMEM156, WAPL, MAP1LC3B, RPL22L1, ITGB1, CDK17, RASA2, STK17B, SQSTM1, ASH1L, ILF3, CREB3L2, PPIP5K2, NUGGC, RSL24D1, CYLD, PSMD14, UPF2, CKLF, MED13L, OXR1, AP3D1, TPP2, IFITM1, BLOC1S6, MT-ND6, PDIA4, SCFD1, SPTBN1, IFI35, PDCD4, RIPOR2, TCF4, IBTK, TCEA1, EBAG9, ARPP19, UBA1, FBH1, XAF1, AC103591.3, CCDC32, SPTY2D1, LMBRD1, IFNG-AS1, RBX1, ANKRD36B, N4BP2L2, TMEM50A, OTULIN, EML4, IFI27L2, ARIH2, CBWD1, VPS36, TFRC, CSDE1, CLINT1, TROVE2, LSM14A, RBM26, EDEM2, ZNF292, MT-ND4L, RFC1, ICAM3, ATP6V0A1, CNPY2, THOC2, ACBD3, CHST2, LUC7L3, HIPK2, SYNE2, FBXW7, SELPLG, MYCBP2, PLD3, TRIP12, ITSN2, ZNF92, CNP, SEL1L3, PNISR, RPL17, POLR2B, GCC2, SNHG25, METTL7A, HSPB11, GOLGB1, TMEM87A, PET100, DUSP22, ABI1, KMT2A, NEMF, GOSR2, SRSF11, PTPN1, NDUFA3, UBR5, CTSA, APOL2, PPP2R5C, AC016745.2, MON2, MDM4, IKZF3, PAPOLA, CD2BP2, SUZ12, ARID4B, AFTPH, RPS27, RBM5, FUBP1, TMC6, RPS17, PIM2, STAT2, NCF1, TMEM256, NKTR, HERC5, CHPF, ATM, EBPL, BIRC6, SETBP1, MT-ND2, VAPA, UQCC2, ADAR, HDAC7, EIF5B, SIL1, CASP10, TLK1, STAT1, PIM1, ATP2A2, SERBP1, EPB41, NDUFB9, LILRB4, HLA-A, SEC13, RPL38, GOLGA4, SEC31A, PPM1K, SCARB2, ATP5ME, TRAF3IP3, HLA-C, ATP5F1E, NXPE3, SLC38A2, ATP2A3, MZT2B, IFI44, FKBP2, BCL2L11, MBNL2, SLAMF7, IFI16, FCRL5, MARK3, CRIP1, IFI44L, ROMO1, SEC24A, PDK1, UGGT1, PARP14, COBLL1, TNFSF10, GLS, ITPR2, EIF1AX, KMT2C, USP34, ARGLU1, ASCC3, TXNDC11, ACO2, CPEB4, MEF2C, FMNL1, NCOA3, AKAP9, MSI2, COX7A2L, TXNDC5, ST6GAL1, ENTPD1, SMAP2, DSTN, PRDM1, TRAM1, C4orf3, HNRNPH1, YWHAE, WIPF1, COPA, OGT, MAN1A1, TRA2A, NSD1, TXNDC15, XRN1, JAK1, RPL27A, AC012368.1, AP2M1, CASP3, PLCG2, TYMP, MDM2, MALAT1, IRF4, HERC2, NDUFB6, FNDC3A, CD38, SP100, MIR4435-2HG, MT-ND3, ANKRD12, PTPN2, SMCHD1, SAMD9L, ATRX, MIF, RNF213, IRF7, TP53INP1, DDX24, MX1, XIST, IFI6, MTRNR2L12, ISG15, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
75 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | plasmacytoid dendritic cell | CL:0000784 (plasmacytoid dendritic cell) | CITE-seq | HLA-DQA2, TCL1A, MS4A6A, HLA-DRB5, MT-ND3, PPP1R14B, UBE2E3, PLA2G16, CLIC3, VIM, JUND, MYADM, NPC2, FCER1G, BRI3, MT-ND1, VEGFB, MT-CO1, PYCARD, RPS11, PTCRA, RGS1, GNAS, RPLP0, AL355075.4, C12orf75, PLXNA4, IDS, MIF4GD, CCDC50, SRGN, ARL4C, AC020916.1, RPL23, TBC1D4, PMEPA1, CYP46A1, S100A10, ID1, CD4, TSPYL2, GZMB, DRD4, KDM6B, RPS20, ZNRF2, CDK2AP2, DUSP5, RUBCN, C12orf57, SCT, TAGLN2, RPS14, RPS18, PTPRE, TMEM8B, SLC1A5, C12orf45, CD52, ALCAM, SEC61B, CRYM, GUK1, CUEDC1, FCGRT | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
76 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | plasmacytoid dendritic cell | CL:0000784 (plasmacytoid dendritic cell) | CITE-seq | DNAJC15, C19orf66, XRN1, SOX4, MGLL, CTSH, HESX1, SH3BGRL, NMI, PTMA, SELL, GLRX, GADD45B, PDIA6, PSMB9, TAP1, DUSP22, H1FX, DDX60, GALNT2, H3F3B, HLA-DQA1, SPATS2L, FXYD5, CD63, STAT2, DRAP1, RASD1, SLC20A1, NAPA, CLEC2B, GLUL, MYBL2, SAMD9, HLA-F, LGMN, PARP9, B2M, CD38, TSC22D1, PHF11, NT5C3A, HSH2D, TNFSF10, IFI6, HLA-E, HLA-C, TXNIP, CAPN2, SP100, HLA-DRB1, HLA-B, TRIM22, IFI35, DDIT4, S100A9, FCHSD2, S100A8, MNDA, HERC5, LAP3, ANXA5, HIST1H1D, LGALS9, HIST1H2AC, OAS1, HLA-A, HIST1H1C, COX5A, IFITM2, OAS2, ADAR, TYMP, UBE2L6, SP110, MX2, USP18, PLSCR1, ZFP36L2, PARP14, HIST1H1E, IFI16, SAMD9L, BST2, IFI44, EPSTI1, STAT1, EIF2AK2, PIM3, ISG20, XAF1, MX1, LY6E, IFI44L, ISG15, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
77 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | platelet | CL:0000233 (platelet) | CITE-seq | PDZK1IP1, TSPAN33, NCOA4, AC147651.1, HEMGN, AQP10, LGALSL, TMEM91, VIM-AS1, HGD, ANAPC5, NCK2, TMEM158, MLH3, FHL1, C19orf33, GNAS, DYNLL1, AMD1, MTRNR2L8, TUBA4A, MPST, CA2, PABPC1, ZCCHC17, CTDSPL, ITGB5, UBXN11, LY6G6F, TUBA1B, ODC1, MGAT4B, PDLIM1, ILK, TACC3, CALD1, TUBA1C, TST, GAPDH, CERS2, MT-CO3, CDKN2D, TPM1, RPA1, AP001189.1, AC090409.1, TMSB4X, INAFM2, CCDC92, PRKAR2B, EMC3, MT-CYB, GNAZ, ACTG1, CYB5R3, DAPP1, ACTN1, PF4, CLDN5, TAGLN2, RNF11, EID1, FCER1G, PTCRA, CENPT, SCN1B, PYCR2, MT-ATP8, CD68, USF2, MYL12A, GSN, PRDX5, MT-ND1, CD9, UBC, PARVB, GP9, PLEK, RAB8A, TNNC2, PPBP, MYL6, NDUFA4, SPINT2, MAP3K7CL, NENF, CAVIN2, YBX1, RPL10, MFSD1, RAB4A, UBE2E3, SH3BGRL, LIMS1, RDH11, ANKRD9, PLEKHO1, MT-ND2, ACTB, MT-ATP6, UQCRH, GRAP2, CXCL5, GNG11, DOK2, MTPN, AP2S1, SRGN, CCL5, MT-ND3 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
78 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | platelet | CL:0000233 (platelet) | CITE-seq | HMG20B, YWHAH, G3BP2, PCP2, RSU1, OAZ1, RPS19BP1, VAPA, UXS1, KCTD20, MYLK, MORF4L1, RPL8, RACK1, HIST1H2AC, HIST1H2AG, FHL2, RPL7A, ABTB1, RPL30, GAS2L1, RPL18A, UCP2, SEC14L1, UBE2F, RPL32, APP, TMEM50A, SERF2, GMFG, RPS16, GPX4, AKIRIN2, ANO6, RPS23, RPL15, H2AFJ, DERA, FTH1, FTL, SELP, TSC22D3, EIF1, CD99, RIOK3, RPS2, CTSD, ADD3, RPS13, RPS19, NAP1L4, BEX3, SVIP, STON2, C12orf76, RPS7, ARHGEF12, UQCR11, CMIP, RPL39, RPS8, SQSTM1, ISCU, CST3, RPL28, YBX3, HLA-E, LCN2, UBE2J1, RPS27, SMIM10L1, HSPB1, EPB41, FRMD3, STRAP, RPL34, HIST1H2BJ, SLC40A1, SET, RPL26, RPL41, ARHGDIB, CNPY3, RPL23A, TMEM140, RPS29, EIF2AK1, RPL37A, JAK1, UBE2B, ATP5F1E, TIMP1, ATP5MPL, CAPN2, MMD, 44085, ADI1, RPS18, NDUFB4, RPL36AL, ATP2A3, CRBN, PAIP2, RPL37, RPS24, ITM2B, TXNIP, UIMC1, TMSB10, HIST1H3H, RPS28, YPEL3, EGFL7, SUB1, PCMT1, HIST1H1C, CFLAR, RPL36, MIR4435-2HG, SMIM5, RPS26, RHOC, PTMA, IFITM2, HTATIP2, IFI27L2, CCDC88C, EVA1B, KIFAP3, EPSTI1, HCST, S100A9, S100A8, CMPK2, LY6E, JCHAIN, IFI6, IFITM3, CST7, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
79 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | erythrocyte | CL:0000232 (erythrocyte) | CITE-seq | FOS, FOSB, S100A9, HBB | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
80 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | erythrocyte | CL:0000232 (erythrocyte) | CITE-seq | ASCC2, HBQ1, ISCA1, CDC34, EIF2AK1, RAD23A, RBX1, STMP1, POLR1D, ANKRD9, METTL9, FAM210B, FKBP8, WDR45, OAZ1, CHPT1, NFE2, PPP1CB, RPIA, MICAL2, WASF2, MAP1LC3B, HK1, LPIN2, SKP1, TMOD1, MARK3, ANP32B, 43898, PIM1, TESC, HPS1, SMIM1, SEC14L1, YBX3, MXI1, EIF1B, PA2G4, MTRNR2L12, SNCA, MKRN1, PRDX6, ODC1, FECH, EPB42, TALDO1, MAP2K3, DCAF12, TRIM58, KRT1, FIS1, NCOA4, ADIPOR1, GYPB, BCL2L1, JCHAIN, YPEL3, DMTN, R3HDM4, BSG, HAGH, OST4, ISCU, HBA2, WNK1, BLVRB, SIAH2, TERF2IP, CCNDBP1, HBA1, RNF10, GUK1, FTH1, PRDX2, RBM38, GMPR, SELENBP1, MPP1, GABARAPL2, ATP5F1E, UBB, GSPT1, SLC4A1, GLRX5, HBM, CA1, ALAS2, AHSP, HBD, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
81 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | T cell | CL:0000084 (T cell) | CITE-seq | JUN, PDZK1IP1, NCOA4, IER2, DUSP1, HOPX, FOSB, JUND, IER5, JUNB, FOS, KLF2, NFKBIA, MT-CYB, NCR3, NR4A2, SERTAD1, AC147651.1, ARL4C, MT-ND3, MT-CO1, RPS14, MT-CO3, MT-ND1, RPL3, MT-ATP6, MT-CO2, MT-ND4 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
82 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | T cell | CL:0000084 (T cell) | CITE-seq | ITM2B, ETS1, IFI44, IRF7, EPSTI1, MIR4435-2HG, TIMP1, LY6E, EIF2AK2, TXNIP, MX1, XAF1, ISG15, JCHAIN, IFI44L, HBG2, S100A9, IFI6, S100A8, IFITM3, IFI27 | N | gene expression | up | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | PBMCs enriched for DCs | |||||||||||
83 | 2021-03-31 | COVID-19 infected patients and age/sex-matched healthy controls (Atlanta, Georgia) | 38 | 90 | years | 12 | T cell (cluster enriched in ISGs) | CL:0000084 (T cell) | CITE-seq | GBP4, MT-CYB, RPS14, RPL4, RPL10 | N | gene expression | down | pooled moderate and severe COVID-19 vs healthy | onset of symptoms | various | days | Severe acute respiratory syndrome coronavirus 2 | ncbi_taxid:2697049 (Severe acute respiratory syndrome coronavirus 2) | occurrence of infectious disease | COVID-19 | moderate and severe | pmid:32788292 | 2020-09-04 | https://pubmed.ncbi.nlm.nih.gov/32788292/ | Suppl Table S4 | Cluster enriched in interferon stimulated genes (ISGs). PBMCs enriched for DCs | |||||||||||
84 | ||||||||||||||||||||||||||||||||||||||
85 | ||||||||||||||||||||||||||||||||||||||
86 | ||||||||||||||||||||||||||||||||||||||
87 | ||||||||||||||||||||||||||||||||||||||
88 | ||||||||||||||||||||||||||||||||||||||
89 | ||||||||||||||||||||||||||||||||||||||
90 | ||||||||||||||||||||||||||||||||||||||
91 | ||||||||||||||||||||||||||||||||||||||
92 | ||||||||||||||||||||||||||||||||||||||
93 | ||||||||||||||||||||||||||||||||||||||
94 | ||||||||||||||||||||||||||||||||||||||
95 | ||||||||||||||||||||||||||||||||||||||
96 | ||||||||||||||||||||||||||||||||||||||
97 | ||||||||||||||||||||||||||||||||||||||
98 | ||||||||||||||||||||||||||||||||||||||
99 | ||||||||||||||||||||||||||||||||||||||
100 | ||||||||||||||||||||||||||||||||||||||
101 | ||||||||||||||||||||||||||||||||||||||
102 | ||||||||||||||||||||||||||||||||||||||
103 | ||||||||||||||||||||||||||||||||||||||
104 | ||||||||||||||||||||||||||||||||||||||
105 |